<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01106495</url>
  </required_header>
  <id_info>
    <org_study_id>EECP-1</org_study_id>
    <nct_id>NCT01106495</nct_id>
  </id_info>
  <brief_title>Effect of Enhanced External Counterpulsation (EECP) on Subclinical Atherosclerosis</brief_title>
  <acronym>SESA</acronym>
  <official_title>Study of the Effect of EECP on Subclinical Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Shear stress maybe the most crucial local factor affecting atherogenesis. The present study
      investigated the effect of exposure to increased shear stress promoted by Enhanced External
      Counterpulsation (EECP) on the progression of subclinical atherosclerosis and the underlying
      inflammation- related molecular mechanisms
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypercholesterolemic subjects with subclinical atherosclerosis will be randomized into two
      groups: standard treatment group and standard treatment plus EECP intervention group. The
      results of ultrasound examination and markers of inflammations will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Intima-media thickness of the carotid artery</measure>
    <time_frame>7 weeks</time_frame>
    <description>Change from baseline in Intima-media thickness of the carotid artery measured by Doppler ultrasound equipment at 7 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in vascular endothelial function</measure>
    <time_frame>7 weeks</time_frame>
    <description>Change from baseline in vascular endothelial function evaluated by flow mediated dilation of the brachial artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum markers of inflammation</measure>
    <time_frame>7 weeks</time_frame>
    <description>Change from baseline in serum markers of inflammation and laboratory parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Enhanced External Counterpulsation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. Patients with subclinical atherosclerosis whose serum LDL high than 160mg/ml receive EECP 1- hour session every working day over a 7 week period. Simvastatin is used to decrease cholesterol level for 7 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects whose LDL higher than 160 mg/dl with subclinical atherosclerosis. Simvastatin is used to decrease cholesterol level for 7 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Enhanced External Counterpulsation (EECP)</intervention_name>
    <description>EECP one hour per day, 5 hours a week for a total of 35- 36 hours over a 7 week period</description>
    <arm_group_label>Enhanced External Counterpulsation</arm_group_label>
    <other_name>EECP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin 40 mg/d for 7 weeks as the guideline- driven standard medical treatment</description>
    <arm_group_label>Enhanced External Counterpulsation</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Statin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20- 70 years old subjects whose LDL higher than 160mg/dl and carotid intima-media
             thickness higher than 75 percent of his age.

        Exclusion Criteria:

          -  Presence of history of coronary heart disease, stroke or atherosclerotic peripheral
             disease. Presence of impaired renal function, connective disease, or infectious
             disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Ma, MD</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Zhang, MD</last_name>
    <phone>862087755766</phone>
    <phone_ext>8161</phone_ext>
    <email>Zhyan3@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat- sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Zhang, MA</last_name>
      <phone>862087755766</phone>
      <phone_ext>8035</phone_ext>
      <email>Zhanglingaben@126.com</email>
    </contact>
    <investigator>
      <last_name>Yan Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>April 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2010</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yan Zhang</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Vascular Endothelium</keyword>
  <keyword>Counterpulsation, External</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

